Publicaciones en las que colabora con JOSÉ ÁNGEL GARCÍA SÁENZ (21)

2024

  1. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

    Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172

2023

  1. Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab

    JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846

2022

  1. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

    Cancers, Vol. 14, Núm. 3

2021

  1. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

    Scientific Reports, Vol. 11, Núm. 1

2019

  1. Breast cancer PAM50 signature: Correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

    BMC Genomics, Vol. 20, Núm. 1

  2. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

    Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829

  2. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification

    Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852

2017

  1. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts

    Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657

  2. Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial (Breast Cancer Research and Treatment, (2016), 156, 3, (507-515), 10.1007/s10549-016-3792-1)

    Breast Cancer Research and Treatment

  3. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer

    Breast Cancer Research and Treatment, Vol. 162, Núm. 1, pp. 181-189

2016

  1. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

    Breast Cancer Research and Treatment, Vol. 156, Núm. 3, pp. 507-515

  2. Review: circulating tumor cells in the practice of breast cancer oncology

    Clinical and Translational Oncology, Vol. 18, Núm. 8, pp. 749-759

2013

  1. Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer

    Oncologist, Vol. 18, Núm. 8, pp. 917-923

2011

  1. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

    Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136

  2. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review

    Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132

2009

  1. Circulating tumor cells in metastatic breast cancer: Timing of blood extraction for analysis

    Anticancer Research, Vol. 29, Núm. 10, pp. 4185-4187

2007

  1. Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid

    Medicina oral, patología oral y cirugía bucal. Ed. inglesa, Vol. 12, Núm. 5, pp. 4

2006

  1. Cáncer de próstata

    Tiempos médicos: revista de educación médica continuada, Núm. 631, pp. 31-36

  2. Significance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal Carcinoma

    Clinical and Translational Oncology, Vol. 8, Núm. 9, pp. 676-680